Which drugs work best for non-cirrhotic metabolic dysfunction-associated steatohepatitis?
For non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the most effective drugs are those that improve metabolism and insulin sensitivity. A 2024 network meta-analysis found that therapies targeting metabolic dysfunction and insulin sensitivity had the most consistent benefits for resolving steatohepatitis and improving fibrosis, with odds ratios of 2.5 to 7.1 compared to placebo 2. Fibroblast growth factor 21 (FGF21) analogs and incretin-based multi-agonists (like tirzepatide and semaglutide) ranked among the leading classes 2. However, even with these drugs, 35% to 70% of treated patients did not meet biopsy endpoints, meaning many still need additional options 2. Lifestyle modification and weight loss remain the cornerstone of management 91011.
What the research says
Other drug classes, such as triglyceride-lowering therapies (fibrates, omega-3 fatty acids, pemafibrate, and novel agents like pegozafermin), show promise in reducing liver fat and improving liver enzymes, but more large-scale studies are needed to confirm their long-term efficacy for MASH 1. Anti-inflammatory and anti-fibrotic agents have shown more variable biopsy responses 2. Placebo responses in MASH trials are notable: about 11% of placebo patients achieve MASH resolution without worsening fibrosis, and 22% show a 5% reduction in liver fat 4. This highlights the importance of weight loss and lifestyle changes, which are consistently associated with histologic improvement 5910.
What to ask your doctor
- Given my current weight and metabolic health, would an incretin-based drug like semaglutide or tirzepatide be appropriate for my MASH?
- What are the expected benefits and side effects of FGF21 analogs or other emerging therapies for non-cirrhotic MASH?
- How much weight loss should I aim for to improve my liver health, and what lifestyle changes are most effective?
- Are there any ongoing clinical trials for MASH that I might be eligible for?
- How will we monitor my response to treatment—through repeat biopsies, imaging, or blood tests?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.